NCM
UTHR icon

Nantahala Capital Management’s United Therapeutics UTHR Stock Holding History

Nantahala Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,700
Closed -$3.47M – 146
2023
Q2 		$3.47M Hold
15,700
– – 0.34% 62
2023
Q1 		$3.52M Buy
+15,700
New +$3.87M 0.27% 61

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nantahala Capital Management's UTHR Position: Q3 2023 in Review

Nantahala Capital Management sold out of United Therapeutics (UTHR) in Q3 2023, closing a stake of 15,700 shares — an estimated $3.47M sold.

Nantahala Capital Management first reported a position in UTHR in Q1 2023 and held it in 2 quarters. The position peaked at $3.52M in Q1 2023. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

  • Nantahala Capital Management reported no remaining United Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Nantahala Capital Management sold 15,700 United Therapeutics shares in Q3 2023, an estimated $3.47M.
  • Nantahala Capital Management first reported a position in United Therapeutics in Q1 2023 and held it in 2 quarters.
  • Nantahala Capital Management's United Therapeutics position peaked at $3.52M in Q1 2023.
  • 508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on Nantahala Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.